Rare Disease Exome
Rare Disease Diagnosis
CommercialActive
Key Facts
About MyOme
MyOme operates at the intersection of genetics, bioinformatics, and clinical care, offering a comprehensive whole-genome-based testing platform. Its core innovation is the integrated Polygenic Risk Score (iPRS™), which combines monogenic and polygenic risk data validated across diverse ancestries. The company targets multiple customer segments, including providers, patients, employers, and healthcare systems, with a focus on making precision medicine actionable in primary care settings. MyOme is a private, commercial-stage company with key partnerships, such as with Illumina and Broad Clinical Labs, enhancing its technological and distribution capabilities.
View full company profileTherapeutic Areas
Other Rare Disease Diagnosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Rare Disease Genome | MyOme | Commercial |
| Exome Sequencing with Patient for Life™ | Ambry Genetics | Commercial |
| Zenith™ Genomics | Natera | Commercial Launch |